DE69334255D1 - Marker für Krebs und biosynthetisches Bindeprotein dafür - Google Patents

Marker für Krebs und biosynthetisches Bindeprotein dafür

Info

Publication number
DE69334255D1
DE69334255D1 DE69334255T DE69334255T DE69334255D1 DE 69334255 D1 DE69334255 D1 DE 69334255D1 DE 69334255 T DE69334255 T DE 69334255T DE 69334255 T DE69334255 T DE 69334255T DE 69334255 D1 DE69334255 D1 DE 69334255D1
Authority
DE
Germany
Prior art keywords
erbb
polypeptide
marker
cancer
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334255T
Other languages
English (en)
Inventor
David B Ring
L L Houston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE69334255D1 publication Critical patent/DE69334255D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
DE69334255T 1992-02-06 1993-02-05 Marker für Krebs und biosynthetisches Bindeprotein dafür Expired - Lifetime DE69334255D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83196792A 1992-02-06 1992-02-06

Publications (1)

Publication Number Publication Date
DE69334255D1 true DE69334255D1 (de) 2009-02-12

Family

ID=25260318

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69333807T Expired - Lifetime DE69333807T2 (de) 1992-02-06 1993-02-05 Marker für krebs und biosynthetisches bindeprotein dafür
DE69334255T Expired - Lifetime DE69334255D1 (de) 1992-02-06 1993-02-05 Marker für Krebs und biosynthetisches Bindeprotein dafür
DE69334351T Expired - Lifetime DE69334351D1 (de) 1992-02-06 1993-02-05 Biosynthetisches Bindeprotein für Tumormarker

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69333807T Expired - Lifetime DE69333807T2 (de) 1992-02-06 1993-02-05 Marker für krebs und biosynthetisches bindeprotein dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69334351T Expired - Lifetime DE69334351D1 (de) 1992-02-06 1993-02-05 Biosynthetisches Bindeprotein für Tumormarker

Country Status (8)

Country Link
US (6) US5534254A (de)
EP (3) EP1514934B1 (de)
JP (8) JPH08500962A (de)
AT (3) ATE419355T1 (de)
AU (1) AU675929B2 (de)
CA (2) CA2129663C (de)
DE (3) DE69333807T2 (de)
WO (1) WO1993016185A2 (de)

Families Citing this family (1304)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US20050058638A1 (en) * 1987-05-21 2005-03-17 Huston James S. Biosynthetic binding proteins for immuno-targeting
EP0368684B2 (de) * 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
CA2100671C (en) * 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
KR100334695B1 (ko) * 1991-08-05 2002-04-27 리차아드제이마세이 표적화된 촉매 단백질에 의해 활성화되는 선구 약제
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US20070031931A1 (en) * 1992-02-06 2007-02-08 Chiron Corporation Biosynthetic binding proteins for immuno-targeting
EP1514934B1 (de) * 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Marker für Krebs und biosynthetisches Bindeprotein dafür
US7754211B2 (en) * 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US20080152586A1 (en) * 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
CA2150262C (en) * 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
ES2126145T3 (es) 1993-09-22 1999-03-16 Medical Res Council Redireccionamiento de anticuerpos.
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
IT1264083B1 (it) * 1993-12-10 1996-09-10 Enea Ente Nuove Tec Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CA2246429C (en) * 1996-03-27 2007-07-24 Genentech, Inc. Erbb3 antibodies
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
DE69739856D1 (de) * 1996-07-03 2010-06-02 Genentech Inc Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
EP0922111B1 (de) * 1996-07-23 2004-12-01 Tanox Pharma B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
NZ333946A (en) * 1996-08-05 2000-09-29 Harvard College MHC binding peptide oligomers
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ATE444760T1 (de) * 1997-01-13 2009-10-15 Univ Emory Glutathion zur behandlung von influenzainfektionen
WO1998033809A1 (en) * 1997-01-31 1998-08-06 The General Hospital Corporation Compositions and methods for imaging gene expression
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
EP0981548A4 (de) 1997-04-30 2005-11-23 Enzon Inc Glykosylierungsfähige einzelkettige antigen-bindende proteine, herstellung und verwendung derselben
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
CA2289665C (en) 1997-06-13 2005-08-09 Genentech, Inc. Protein recovery by chromatography followed by filtration upon a charged layer
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (de) 1997-12-12 2012-12-19 Genentech, Inc. Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
EP1941905A1 (de) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
AU4009899A (en) * 1998-05-23 1999-12-13 Tanox, Inc. Molecules targeting cd40 and tumor cells
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
DE19831429A1 (de) * 1998-07-07 2000-04-27 Jerini Biotools Gmbh Verfahren zur Identifizierung und chemisch-synthetischen Nachahmung von Bindungsstellen auf Proteinen
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7118743B2 (en) 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
AU1727500A (en) * 1998-11-17 2000-06-05 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
EP1950300A3 (de) 1998-11-18 2011-03-23 Genentech, Inc. Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
CA2370466C (en) 1999-06-25 2011-02-08 Sharon Erickson Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
MXPA01013395A (es) * 1999-06-25 2003-09-04 Genentech Inc Tratamiento de cancer de prostata con anticuerpos anti-erbb2.
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
IL146954A0 (en) 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
KR20090126330A (ko) 1999-08-27 2009-12-08 제넨테크, 인크. 항-ErbB2 항체 투여 치료 방법
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6794494B1 (en) * 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
BR0108001A (pt) 2000-02-01 2004-01-06 Tanox Inc Moléculas ativadoras de apc com ligação para cd-40
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US6319694B1 (en) * 2000-03-03 2001-11-20 Genopsys, Inc. Random truncation and amplification of nucleic acid
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CA2403425C (en) 2000-04-11 2013-08-27 Genentech, Inc. Multivalent antibodies and uses therefor
EP1284752A4 (de) * 2000-04-26 2004-08-18 Elusys Therapeutics Inc Biospezifische moleküle und deren verwendung
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
DE60139768D1 (de) 2000-05-19 2009-10-15 Genentech Inc Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine k
EP1283721A4 (de) * 2000-05-26 2004-07-07 Smithkline Beecham Corp Anti-rank-ligand-bindende monoklonale antikörper die nützlich zur behandlung von durch den rank-liganden verursachten krankheiten sind
EP2052742A1 (de) 2000-06-20 2009-04-29 Biogen Idec Inc. Behandlung von B-Zellen-assoziierten Krankheiten wie Malignitäten und Autoimmunkrankheiten unter Verwendung einer Kombination aus kalten Anti-CD20-Antikörpern und radioaktiv markierten Anti-CD22-Antikörpern
GB0027328D0 (en) * 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
YU17503A (sh) * 2000-09-07 2006-05-25 Schering Aktiengesellschaft Receptor oblasti (ii) edb-fibronektina
US20020086814A1 (en) * 2000-11-15 2002-07-04 Brian Storrie B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging
NZ569856A (en) 2001-01-05 2010-03-26 Pfizer Antibodies to insulin-like growth factor 1 receptor
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
BR0209114A (pt) 2001-04-24 2004-07-13 Merck Patent Gmbh Terapia de combinação usando agentes antiangiogênicos e tnfalfa
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
ATE522623T1 (de) 2001-06-20 2011-09-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
EP2153843B1 (de) 2001-09-18 2012-08-15 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005049075A2 (en) 2003-11-17 2005-06-02 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP2005525095A (ja) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
DE60325334D1 (de) 2002-02-05 2009-01-29 Genentech Inc Proteinaufreinigung
US6869787B2 (en) * 2002-02-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Ricin vaccine and methods of making and using thereof
ES2429112T3 (es) 2002-04-10 2013-11-13 Genentech, Inc. Variantes de anticuerpos anti-HER2
AU2003262190A1 (en) * 2002-04-11 2003-10-27 Amgen Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
EP2011886A3 (de) 2002-04-16 2009-02-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
WO2004003155A2 (en) 2002-06-28 2004-01-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
EP1585966B8 (de) 2002-07-15 2012-03-07 F. Hoffmann-La Roche AG Behandlung von Krebs mit dem anti-ErbB2-Antikörper rhuMAb 2C4
DK2332996T3 (en) 2002-09-11 2014-12-15 Genentech Inc Purification of anti-Her2 antibodies
AU2002951853A0 (en) * 2002-10-04 2002-10-24 Commonwealth Scientific And Industrial Research Organisation Crystal structure of erbb2 and uses thereof
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20040258685A1 (en) * 2002-11-21 2004-12-23 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
EP1585743B1 (de) * 2002-12-19 2007-05-23 Pfizer Inc. 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
EP1592776A4 (de) 2003-02-01 2008-06-04 Tanox Inc Hochaffine anti-mensch-ige-antikörper
WO2004076412A2 (en) 2003-02-26 2004-09-10 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
BRPI0409230A (pt) * 2003-04-03 2006-03-28 Pfizer formas de dosagem compreendendo ag013736
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
RU2358762C9 (ru) 2003-04-09 2016-10-10 Джинентех, Инк. Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN1829741A (zh) 2003-05-30 2006-09-06 健泰科生物技术公司 利用抗-vegf抗体的治疗
US20050095243A1 (en) 2003-06-05 2005-05-05 Genentech, Inc. Combination therapy for B cell disorders
ES2527102T3 (es) * 2003-06-19 2015-01-20 Genentech, Inc. Composiciones y métodos para el tratamiento de trastornos relacionados con la coagulación
SI1641822T1 (sl) 2003-07-08 2013-08-30 Genentech, Inc. IL-17 A/F heterologni polipeptidi in njihove terapevtske uporabe
US7485704B2 (en) 2003-07-28 2009-02-03 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7589181B2 (en) * 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
WO2005021553A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
ATE412655T1 (de) * 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2486933B1 (de) 2003-11-06 2015-10-28 Seattle Genetics, Inc. Mit Antikörpern konjugierte Monomethylvalinverbindungen
ES2347152T3 (es) * 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
ATE452147T1 (de) 2004-02-19 2010-01-15 Genentech Inc Antikörper mit korrigierten cdr
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック, インコーポレイテッド ヒト化抗TGF−β抗体
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
CN114053429A (zh) 2004-06-01 2022-02-18 健泰科生物技术公司 抗体-药物偶联物和方法
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
EP2322217A3 (de) * 2004-07-16 2011-09-28 Pfizer Products Inc. Kombinationsbehandlung für nicht-hämatologische bösartige Erkrankungen mit einem anti-IGF-1R-Antikörper
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
DE602005019167D1 (de) 2004-07-20 2010-03-18 Genentech Inc Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
EA013678B1 (ru) 2004-08-26 2010-06-30 Пфайзер Инк. Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
EP1786777A1 (de) * 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroarylverbindungen als proteintyrosinkinaseinhibitoren
PT1784396E (pt) * 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
ATE432469T1 (de) * 2004-09-21 2009-06-15 Us Gov Health & Human Serv Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
EP1841793B1 (de) 2005-01-07 2010-03-31 Diadexus, Inc. Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
EP1846030B1 (de) 2005-01-21 2018-11-21 Genentech, Inc. Fixe dosierung von her-antikörpern
MX2007009566A (es) * 2005-02-09 2009-02-16 Genentech Inc Inhibicion de la difusion de la her2 con antagonistas de la metaloproteasa de matriz.
JP5651285B2 (ja) 2005-02-15 2015-01-07 デューク ユニバーシティ 抗cd19抗体および腫瘍学における使用
NZ590431A (en) 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
JP4324636B2 (ja) 2005-03-31 2009-09-02 アジェンシス,インコーポレイテッド 161p2f10bタンパク質に結合する抗体および関連分子
EP2444421A1 (de) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin-Antikörper
EP2221316A1 (de) 2005-05-05 2010-08-25 Duke University CD19-Antikörper-Therapie für Autoimmunerkrankungen
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
EP1995321A2 (de) 2005-08-15 2008-11-26 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
ES2681656T3 (es) 2005-09-07 2018-09-14 Amgen Fremont Inc. Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1)
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
AU2006311803C1 (en) 2005-11-04 2015-05-14 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
WO2007126439A2 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CN103396485B (zh) 2005-12-15 2016-08-10 健泰科生物技术公司 靶向多聚泛蛋白的方法和组合物
US7625759B2 (en) 2005-12-19 2009-12-01 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
WO2007130697A2 (en) 2006-01-05 2007-11-15 Genentech, Inc. Anti-ephb4 antibodies and methods using same
KR101383472B1 (ko) * 2006-01-13 2014-04-08 아이알엠 엘엘씨 알레르기 질병 치료를 위한 흉선 간질 림포포이에틴수용체에 대한 항체
EA201200560A1 (ru) 2006-01-18 2012-09-28 Мерк Патент Гмбх Специфическая терапия, использующая интегриновые лиганды для лечения рака
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP1996716B1 (de) 2006-03-20 2011-05-11 The Regents of the University of California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
EP2389946A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2082645A1 (de) 2006-04-19 2009-07-29 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
EP2021338A1 (de) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylaminosäurederivate und pharmazeutische zusammensetzung davon
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
SG172656A1 (en) 2006-05-30 2011-07-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
DK2046809T3 (en) 2006-07-19 2017-03-13 Univ Pennsylvania WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS
WO2008016431A2 (en) 2006-07-29 2008-02-07 Robert Lamar Bjork Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
EP2057465A4 (de) 2006-08-09 2010-04-21 Homestead Clinical Corp Organspezifische proteine und anwendungsverfahren dafür
JP2010501172A (ja) 2006-08-25 2010-01-21 オンコセラピー・サイエンス株式会社 肺癌に対する予後マーカーおよび治療標的
ES2383710T3 (es) 2006-09-08 2012-06-25 Medimmune, Llc Anticuerpos anti-CD19 humanizados y su uso en el tratamiento de tumores, trasplantes y enfermedades autoinmunes
EP2469283B1 (de) 2006-09-08 2014-01-15 The Chancellor, Masters and Scholars of the University of Oxford Klinische Diagnose von Leberfibrose mithilfe APOL1 als menschlichen Serumprotein-Biomarker
US20080076139A1 (en) 2006-09-21 2008-03-27 Sharat Singh Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
AU2007319359A1 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ovr110抗体組成物および使用方法
EP2610267A1 (de) 2006-12-18 2013-07-03 Genentech, Inc. Antagonistische Antikörper gegen NOTCH-3 und ihre Verwendung zur Prävention und Behandlung von NOTCH-3-vermittelten Krankheiten
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
CN101605561A (zh) * 2006-12-22 2009-12-16 诺韦利克斯治疗有限公司 通过至少一种表皮生长因子受体特异性抗体或其衍生物的糖尿病治疗
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
CN101652389A (zh) 2007-02-09 2010-02-17 健泰科生物技术公司 抗robo4抗体及其用途
KR101508397B1 (ko) 2007-02-22 2015-04-08 제넨테크, 인크. 염증성 장 질환의 검출 방법
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2076289B1 (de) 2007-04-13 2014-11-12 Dana-Farber Cancer Institute, Inc. Methoden zur behandlung von erbb-therapie resistenten krebs
EP2703011A3 (de) 2007-05-07 2014-03-26 MedImmune, LLC Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
US20090163698A1 (en) * 2007-05-11 2009-06-25 John Joseph Grigsby Method for Preparing Antibody Conjugates
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US20100298156A1 (en) * 2007-06-08 2010-11-25 Si Tuen Lee-Hoeflich Gene expression markers of tumor resistance to her2 inhibitor treatment
CN112480255A (zh) 2007-07-09 2021-03-12 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原
NZ602024A (en) 2007-07-16 2014-04-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
JP2010533495A (ja) 2007-07-16 2010-10-28 ジェネンテック, インコーポレイテッド ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用
US8709731B2 (en) 2007-08-24 2014-04-29 Oncotherapy Science, Inc. DKK1 oncogene as therapeutic target for cancer and a diagnosing marker
CN101855346A (zh) 2007-08-24 2010-10-06 肿瘤疗法科学股份有限公司 Pkib和naaladl2用作前列腺癌治疗和诊断的靶基因
BRPI0815769A2 (pt) 2007-08-24 2017-08-08 Oncotherapy Science Inc Ebi3, dlx5, nptx1 e cdkn3 como genes alvo da terapia e diagnóstico de câncer de pulmão
CN111909273A (zh) 2007-08-29 2020-11-10 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体
EP2185574B1 (de) 2007-09-07 2013-05-08 Agensys, Inc. An 24p4c12-proteine bindende antikörper und zugehörige moleküle
TWI464262B (zh) 2007-09-26 2014-12-11 中外製藥股份有限公司 抗體固定區的變異
ES2502217T3 (es) 2007-10-02 2014-10-03 Genentech, Inc. Antagonistas de NLRR-1 y sus usos
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
EP2233149B1 (de) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Kombination von Transmembran-Aktivator und Calcium-Modulator und Cyclophilin Ligand Interaktor (TACI) und anti-CD20 Mitteln zur Behandlung von Autoimmunerkrankungen
ES2533266T5 (es) 2007-10-30 2018-04-18 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
RU2503460C2 (ru) 2007-11-07 2014-01-10 Дженентек Инк. Применение противомикробного полипептида для лечения микробных нарушений
CN104059143A (zh) 2007-11-12 2014-09-24 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
CN101970689A (zh) 2007-11-29 2011-02-09 健泰科生物技术公司 炎性肠病的基因表达标志物
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP2222706B2 (de) 2007-12-14 2016-08-10 Novo Nordisk A/S Antikörper gegen menschliches nkg2d und gebrauch davon
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
WO2009094561A1 (en) * 2008-01-24 2009-07-30 The Government Of The United States Of America As Represented By The Secretary Of The Departmentof Induced internalization of surface receptors
EP2628753A1 (de) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanisierter monoklonaler Anti-human-NKG2A-Antikörper
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
NZ587132A (en) 2008-01-31 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Egfrに結合する操作されたタンパク質に基づく標的化された治療薬
MX2010009140A (es) 2008-02-25 2010-12-20 Prometheus Lab Inc Seleccion de farmacos para terapia de cancer de mama utilizando matrices basadas en anticuerpos.
JP5544309B2 (ja) 2008-03-10 2014-07-09 セラクローン サイエンシーズ, インコーポレイテッド サイトメガロウイルス感染の治療および診断のための組成物および方法
HUE035182T2 (hu) 2008-03-18 2018-05-02 Genentech Inc Anti-HER2 antitest-hatóanyag-konjugátum és pertuzumab kombinációi
ES2354661B1 (es) 2008-05-08 2012-02-01 Consejo Superior De Investigaciones Científicas (Csic) Método para generar anticuerpos monoclonales que reconocen antígenos de membrana de células progenitoras neurales, anticuerpos producidos por dicho método, y usos.
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US20100029675A1 (en) * 2008-07-25 2010-02-04 Hwang Soo-In Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
PL2848625T3 (pl) 2008-08-14 2020-01-31 Genentech, Inc. Sposoby usuwania zanieczyszczeń za pomocą chromatografii membranowej jonowymiennej z zastąpieniem macierzystego białka
KR101442323B1 (ko) 2008-09-07 2014-09-25 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
US8476410B2 (en) 2008-10-16 2013-07-02 University of Pittsburgh—of the Commonwealth System of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
WO2010048446A2 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
CA2779436A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
CN104922669A (zh) 2008-11-13 2015-09-23 通用医疗公司 用于通过调整bmp-6来调节铁稳态的方法和组合物
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
DK2752189T3 (en) 2008-11-22 2017-01-16 Hoffmann La Roche APPLICATION OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
CA2740806C (en) 2008-12-09 2021-07-20 Bryan Irving Anti-pd-l1 antibodies and their use to enhance t-cell function
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
EP2370561B1 (de) 2008-12-16 2019-08-07 EMD Millipore Corporation Rührkesselreaktor und verfahren
WO2010080528A1 (en) 2008-12-17 2010-07-15 Genentech, Inc. Hepatitis c virus combination therapy
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2749846C (en) 2009-01-15 2018-08-07 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-3
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010106535A1 (en) 2009-03-15 2010-09-23 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
KR20130080871A (ko) 2009-03-20 2013-07-15 제넨테크, 인크. 이중특이적 항-her 항체
CN102378767B (zh) 2009-03-25 2015-01-14 健泰科生物技术公司 抗-fgfr3抗体及其使用方法
KR101766927B1 (ko) 2009-04-01 2017-08-09 제넨테크, 인크. 인슐린 저항성 장애의 치료
EP2414399A1 (de) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Anti-fcrh5-antikörper und immunkonjugate und anwendungsverfahren
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
US8753631B2 (en) * 2009-05-01 2014-06-17 New York University Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
JP5813630B2 (ja) 2009-05-14 2015-11-17 ザ チャンセラー,マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード 微量ヒト血漿タンパク質バイオマーカーの新規なパネルを使用した肝線維症の臨床診断
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CA2763275A1 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP2012531418A (ja) 2009-06-23 2012-12-10 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体タンパク質に結合する二重特異性抗体
KR20120051002A (ko) 2009-07-07 2012-05-21 제넨테크, 인크. 자가면역 탈수초성 질환의 진단 및 치료
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
JP2012533322A (ja) 2009-07-20 2012-12-27 ジェネンテック, インコーポレイテッド クローン病のための遺伝子発現マーカー
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
US20110027275A1 (en) 2009-07-31 2011-02-03 Napoleone Ferrara Inhibition of tumor metastasis
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
WO2011019679A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Ccr2 inhibitors for treating conditions of the eye
PT2464725T (pt) 2009-08-11 2020-05-21 Hoffmann La Roche Produção de proteínas em meios de cultura celular isentos de glutamina
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
CN102573909A (zh) 2009-08-15 2012-07-11 霍夫曼-拉罗奇有限公司 抗血管发生疗法用于治疗先前治疗过的乳腺癌
CA2772194A1 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
CA2777934A1 (en) 2009-10-20 2011-04-28 Prometheus Laboratories Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
TW201121566A (en) 2009-10-22 2011-07-01 Genentech Inc Anti-hepsin antibodies and methods using same
CN104043126A (zh) 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
EP2496600A1 (de) 2009-11-04 2012-09-12 Fabrus LLC Verfahren zur optimierung von antikörpern auf der basis von affinitätsreifung
JP6173690B2 (ja) 2009-11-05 2017-08-02 ジェネンテック, インコーポレイテッド 異種ポリペプチドの分泌のための方法及び組成物
MX2012006072A (es) 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
CN102753194B (zh) 2009-12-02 2015-07-08 伊麦吉纳博公司 靶向人前列腺特异性膜抗原的j591微抗体和双抗体
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック, インコーポレイテッド 抗vegf−c抗体及びその使用方法
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
JP5728718B2 (ja) 2009-12-28 2015-06-03 オンコセラピー・サイエンス株式会社 抗cdh3抗体およびその使用
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
DK2534153T3 (en) 2010-02-12 2017-01-09 Pfizer Salts and polymorphs of 8-fluoro-2- {4 - [(methylamino} methyl] phenyl} -1,3,4,5-tetrahydro-6H-azepino [5,4,3-cd] indole-6-one
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011106222A2 (en) * 2010-02-23 2011-09-01 Corning Incorporated Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
BR112012020373A8 (pt) 2010-02-23 2018-01-02 Genentech Inc anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
KR101839161B1 (ko) 2010-02-23 2018-03-16 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011116396A2 (en) 2010-03-19 2011-09-22 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
BR112012022044A2 (pt) 2010-03-24 2020-08-25 Genentech Inc ''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
DK2568976T3 (en) 2010-05-10 2016-01-11 Academia Sinica Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
KR101827855B1 (ko) 2010-05-17 2018-02-12 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
NZ603648A (en) 2010-05-25 2014-12-24 Genentech Inc Methods of purifying polypeptides
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
ES2599412T3 (es) 2010-05-28 2017-02-01 F. Hoffmann-La Roche Ag Disminución del nivel de lactato y aumento de la producción de polipéptidos regulando por disminución la expresión de la lactato deshidrogenasa y de la piruvato deshidrogenasa quinasa
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
EP2577310B1 (de) 2010-06-03 2018-11-14 F.Hoffmann-La Roche Ag Immun-pet-bildgebung von antikörpern und immunkonjugaten sowie ihre verwendungen
SG10201600791TA (en) 2010-06-08 2016-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
AU2011268356B2 (en) 2010-06-16 2013-09-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
CA2794731C (en) 2010-06-18 2019-03-19 Genentech, Inc. Anti-axl antibodies and methods of use
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
KR20130120439A (ko) 2010-07-09 2013-11-04 제넨테크, 인크. 항-뉴로필린 항체 및 사용 방법
US9220771B2 (en) 2010-07-16 2015-12-29 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2012012750A1 (en) 2010-07-23 2012-01-26 Trustees Of Boston University ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
CN103153341B (zh) 2010-08-03 2015-05-27 霍夫曼-拉罗奇有限公司 慢性淋巴细胞性白血病(cll)生物标志物
KR20130049196A (ko) 2010-08-05 2013-05-13 에프. 호프만-라 로슈 아게 항-mhc 항체 항-바이러스성 사이토카인 융합 단백질
EP2603237A4 (de) 2010-08-12 2014-05-21 Theraclone Sciences Inc Anti-hämagglutinin-antikörperzusammensetzungen und verfahren zu ihrer anwendung
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
US9011847B2 (en) 2010-08-13 2015-04-21 Roche Glycart, AG Anti-FAP antibodies and methods of use
MX2013001336A (es) 2010-08-13 2013-03-08 Roche Glycart Ag Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
EP2609117B1 (de) 2010-08-25 2015-09-16 F.Hoffmann-La Roche Ag Antikörper gegen il-18r1 und ihre verwendung
KR20130103734A (ko) 2010-08-31 2013-09-24 제넨테크, 인크. 바이오마커 및 치료 방법
CA2809837C (en) 2010-08-31 2019-12-31 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
EP2630134B9 (de) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivate als modulatoren des smoothened rezeptors
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2012075333A2 (en) 2010-12-02 2012-06-07 Prometheus Laboratories Inc. Her2delta16 peptides
MX371228B (es) 2010-12-16 2020-01-10 Genentech Inc Anticuerpos antiperiostina, kits, composiciones y su uso en la medición de periostina total.
EP2655418B1 (de) 2010-12-20 2017-10-04 F. Hoffmann-La Roche AG Anti-mesothelin-antikörper und immunkonjugate
BR112013015687A2 (pt) 2010-12-22 2016-10-11 Genentech Inc anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
CN103384828A (zh) 2010-12-23 2013-11-06 雀巢产品技术援助有限公司 使用基于抗体的阵列进行恶性癌症疗法的药物选择
EP2659269B1 (de) 2010-12-23 2016-10-26 Roche Diagniostics GmbH Erkennung von posttranslational modifiziertem polypeptid durch ein bivalentes bindungsmolekül
CA2817455C (en) 2010-12-23 2019-04-16 F. Hoffmann-La Roche Ag Detection of a polypeptide dimer by a bivalent binding agent
EP2655414B1 (de) 2010-12-23 2018-08-29 Roche Diagniostics GmbH Bispezifisches bindungsmolekül
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
ES2883371T3 (es) 2011-02-10 2021-12-07 Roche Glycart Ag Polipéptidos de interleucina 2 mutantes
EP2672999A2 (de) 2011-02-10 2013-12-18 Roche Glycart AG Verbesserte immuntherapie
EP2675478A4 (de) 2011-02-14 2015-06-10 Theraclone Sciences Inc Zusammensetzungen und verfahren zur therapie und diagnose von grippe
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 一価抗原結合タンパク質
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
EP2681245B1 (de) 2011-03-03 2018-05-09 Zymeworks Inc. Entwurf und konstrukte für ein multivalentes heteromultimeres gerüst
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
DK2683643T3 (da) 2011-03-09 2019-08-12 Richard G Pestell Prostatacancercellelinjer, gensignaturer og anvendelser deraf
AU2012229188A1 (en) 2011-03-15 2013-09-26 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2686014A1 (de) 2011-03-16 2014-01-22 Sanofi Verwendung eines antikörperähnlichen proteins mit dualer v-region
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
CA2831732C (en) 2011-03-31 2019-12-31 Genentech, Inc. Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
MX342240B (es) 2011-04-07 2016-09-21 Genentech Inc Anticuerpos anti-fgfr4 y metodos de uso.
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
EP3536708A1 (de) 2011-04-19 2019-09-11 Pfizer Inc Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs
CN103502273A (zh) 2011-04-20 2014-01-08 罗氏格黎卡特股份公司 用于pH依赖性通过血脑屏障的方法和构建体
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
EA030462B1 (ru) 2011-05-16 2018-08-31 Дженентек, Инк. Агонисты fgfr1 и способы их применения
MY166974A (en) 2011-06-15 2018-07-27 Hoffmann La Roche Anti-human epo receptor antibodies and method of use
CN103781493A (zh) 2011-06-30 2014-05-07 霍夫曼-拉罗奇有限公司 抗c-met抗体配制剂
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
JP6261499B2 (ja) 2011-07-11 2018-01-17 グレンマーク ファーマシューティカルズ, エセ.アー. Ox40と結合する抗体およびその使用
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
CA2842481A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
MX352101B (es) 2011-08-23 2017-11-08 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t.
RU2014109038A (ru) 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
MY171038A (en) 2011-08-23 2019-09-23 Roche Glycart Ag Bispecific antigen binding molecules
EP2747781B1 (de) 2011-08-23 2017-11-15 Roche Glycart AG Bispezifische antikörper spezifisch für t-zell-aktivierende antigene und ein tumorantigen sowie verwendungsverfahren
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
GB201212550D0 (en) 2012-07-13 2012-08-29 Novartis Ag B cell assay
ES2553456T3 (es) 2011-09-02 2015-12-09 Nestec S.A. Perfilado de proteínas de ruta de señal para determinar una eficacia terapéutica
CN103930781A (zh) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 促进分化的方法
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
PE20141228A1 (es) 2011-09-22 2014-10-01 Pfizer Derivados de pirrolopirimidina y purina
WO2013050725A1 (en) 2011-10-04 2013-04-11 King's College London Ige anti -hmw-maa antibody
CA2849011A1 (en) 2011-10-05 2013-04-11 Genentech, Inc. Methods of treating liver conditions using notch2 antagonists
MX2014004022A (es) 2011-10-14 2014-04-30 Genentech Inc Anticuerpos anti-htra1 y metodos de uso.
RU2014119426A (ru) 2011-10-15 2015-11-20 Дженентек, Инк. Способы применения антагонистов scd1
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014009953A2 (pt) 2011-10-28 2017-12-05 Genentech Inc método de inibição do crescimento de tumores, de tratamento de melanoma, artigo industrializado e uso
SI2773438T2 (sl) 2011-11-02 2022-05-31 F.Hoffmann-La Roche Ag Izpiralna kromatografija s preobremenitvijo
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
RU2014124842A (ru) 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
WO2013078377A1 (en) 2011-11-23 2013-05-30 Igenica, Inc. Anti-cd98 antibodies and methods of use thereof
JP6219304B2 (ja) 2011-11-29 2017-10-25 ジェネンテック, インコーポレイテッド 前立腺癌分析のための組成物及び方法
EP2785864A2 (de) 2011-11-30 2014-10-08 F. Hoffmann-La Roche AG Erbb3-mutationen bei krebs
EP2788024A1 (de) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antikörper-formulierung
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
SG11201403223PA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
CN107119073A (zh) 2011-12-22 2017-09-01 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
CA2859376C (en) 2011-12-22 2022-04-19 Genentech, Inc. Use of ion exchange chromatography for improving downstream chromatography steps for purification of antibodies
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
TW201335187A (zh) 2012-01-18 2013-09-01 Genentech Inc 抗lrp5抗體及使用方法
CN104168920A (zh) 2012-01-18 2014-11-26 霍夫曼-拉罗奇有限公司 使用fgf19调控剂的方法
MX2014009043A (es) 2012-01-31 2014-10-14 Genentech Inc Anticuerpos anti-ige y sus metodos de uso.
WO2013113641A1 (en) 2012-01-31 2013-08-08 Roche Glycart Ag Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
JP6545959B2 (ja) 2012-02-11 2019-07-17 ジェネンテック, インコーポレイテッド Rスポンジン転位およびその使用方法
EP2814587B1 (de) 2012-02-15 2018-05-02 F.Hoffmann-La Roche Ag Affinitätschromatographie auf fc-rezeptor-basis
KR20140130455A (ko) 2012-03-02 2014-11-10 로슈 글리카트 아게 Adcc-강화 항체를 사용한 암 치료용 예측 바이오마커
NZ630020A (en) 2012-03-08 2016-08-26 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
MX2014011500A (es) 2012-03-27 2014-12-05 Genentech Inc Diagnosticos y tratamientos relacionados a inhibidores her3.
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
TW201402609A (zh) 2012-05-01 2014-01-16 Genentech Inc 抗pmel17抗體及免疫結合物
EP2847230B1 (de) 2012-05-10 2020-08-12 Zymeworks Inc. Heteromultimerkonstrukte aus schweren immunoglobulinketten mit mutationen in der fc-domäne
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP2861302A4 (de) 2012-05-14 2016-08-24 Prostagene Llc Verwendung von ccr5-modulatoren zur behandlung von krebs
EP2852840B1 (de) 2012-05-23 2019-10-09 F.Hoffmann-La Roche Ag Auswahlverfahren für therapeutika
KR20150023679A (ko) 2012-06-08 2015-03-05 그렌마크 파머수티칼스 에스. 아. 아미노산 치환을 갖는 인간화된 항-TrkA 항체
JP2015530867A (ja) 2012-06-15 2015-10-29 ジェネンテック, インコーポレイテッド 抗pcsk9抗体、製剤、投薬、及び使用方法
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
WO2014001326A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
KR20150030755A (ko) 2012-07-04 2015-03-20 에프. 호프만-라 로슈 아게 항-바이오틴 항체 및 사용 방법
PL2869837T3 (pl) 2012-07-04 2017-03-31 F.Hoffmann-La Roche Ag Przeciwciała przeciw teofilinie i sposoby ich stosowania
PL2869848T3 (pl) 2012-07-04 2017-04-28 F.Hoffmann-La Roche Ag Połączone kowalencyjnie koniugaty antygen-przeciwciało
CN110042114A (zh) 2012-07-05 2019-07-23 弗·哈夫曼-拉罗切有限公司 表达和分泌系统
AU2013288932A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti - CD79b antibodies
IN2014DN10652A (de) 2012-07-09 2015-09-11 Genentech Inc
CN104540524A (zh) 2012-07-09 2015-04-22 基因泰克公司 包含抗cd22抗体的免疫缀合物
CA2874904A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
MA37794B1 (fr) 2012-07-13 2017-07-31 Roche Glycart Ag Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
IN2015DN01115A (de) 2012-07-13 2015-06-26 Zymeworks Inc
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
KR102163588B1 (ko) 2012-08-07 2020-10-12 로슈 글리카트 아게 감소된 및 증가된 효과기 기능을 갖도록 조작된 2개의 항체를 포함하는 조성물
EA201500208A1 (ru) 2012-08-08 2015-07-30 Роше Гликарт Аг Слитые белки, содержащие интерлейкин-10, и их применения
WO2014023709A1 (en) 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
SG11201500881XA (en) 2012-09-14 2015-03-30 Hoffmann La Roche Method for the production and selection of molecules comprising at least two different entities and uses thereof
PL2903691T3 (pl) 2012-10-05 2019-10-31 Hoffmann La Roche Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
JP2015533832A (ja) 2012-10-09 2015-11-26 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗C16orf54抗体およびその使用方法
DK2909181T3 (da) 2012-10-16 2017-11-20 Tolero Pharmaceuticals Inc PKM2-modulatorer og fremgangsmåder til anvendelse deraf
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3
CN104968367B (zh) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
US9810670B2 (en) 2012-11-15 2017-11-07 Genentech, Inc. Ionic strength-mediated pH gradient ion exchange chromatography
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
SG11201505186SA (en) 2013-01-02 2015-07-30 Glenmark Pharmaceuticals Sa Antibodies that bind to tl1a and their uses
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
EP2961770A1 (de) 2013-02-26 2016-01-06 Roche Glycart AG Bispezifische antigenbindende moleküle zur t-zellen-aktivierung
RU2015140921A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Антитела к mcsp
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2902263A1 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
KR102238379B1 (ko) 2013-03-13 2021-04-09 제넨테크, 인크. 감소된 산화를 갖는 제제
RU2019120404A (ru) 2013-03-13 2019-08-06 Дженентек, Инк. Составы антител
RS57813B1 (sr) 2013-03-13 2018-12-31 Hoffmann La Roche Formulacije sa smanjenom oksidacijom
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2968565A2 (de) 2013-03-14 2016-01-20 Genentech, Inc. Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
CA2903480A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
MX2015012062A (es) 2013-03-14 2016-05-05 Tolero Pharmaceuticals Inc Inhibidores de jak2 y alk2 y metodos para su uso.
KR20150127199A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 항-b7-h4 항체 및 면역접합체
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
EP2970471A2 (de) 2013-03-15 2016-01-20 F. Hoffmann-La Roche AG Anti-crth2-antikörper und deren verwendung
WO2014151866A1 (en) 2013-03-15 2014-09-25 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
EP2972373B1 (de) 2013-03-15 2019-10-09 F.Hoffmann-La Roche Ag Biomarker und verfahren zur behandlung von pd-1 und pd-l1-verwandten leiden
CN105339001A (zh) 2013-03-15 2016-02-17 基因泰克公司 治疗癌症和预防癌症耐药性的方法
ES2798307T3 (es) 2013-03-15 2020-12-10 Hoffmann La Roche Composiciones de cultivo de células con antioxidantes y procedimientos para la producción de polipéptidos
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
JP2016513478A (ja) 2013-03-15 2016-05-16 ジェネンテック, インコーポレイテッド 細胞培養培地及び抗体を産生する方法
SI2976361T1 (sl) 2013-03-18 2018-11-30 Biocerox Products B.V. Humanizirana ANTI-CD134 (OX40) protitelesa in njih uporaba
BR112015024856A2 (pt) 2013-03-27 2018-04-17 Genentech Inc métodos de determinação ou de monitoramento
WO2014169076A1 (en) 2013-04-09 2014-10-16 Annexon,,Inc. Methods of treatment for neuromyelitis optica
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
KR102293064B1 (ko) 2013-05-20 2021-08-23 제넨테크, 인크. 항-트랜스페린 수용체 항체 및 사용 방법
RU2015155590A (ru) 2013-05-24 2017-06-29 Нестек С.А. Путеспецифичные маркеры для диагностики синдрома раздраженного кишечника
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
EA037325B1 (ru) 2013-07-09 2021-03-12 Аннексон, Инк. Антитела против фактора комплемента c1q и их применения
MX368107B (es) 2013-07-12 2019-09-18 Genentech Inc Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
EP3022303B1 (de) * 2013-07-17 2023-11-01 Foundation Medicine, Inc. Verfahren zur behandlung von urothelialen karzinomen
EP3022221B1 (de) 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanisierte antikörper mit ultralangen komplementaritätsbestimmenden regionen
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
BR112016002845A2 (pt) 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
RU2016112549A (ru) 2013-09-05 2017-10-10 Дженентек, Инк. Способ для повторного использования хроматографии
AU2014317889B2 (en) 2013-09-06 2020-03-05 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
KR20160055253A (ko) 2013-09-12 2016-05-17 할로자임, 아이엔씨 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
NZ718144A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック, インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
WO2015042108A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
AU2014324703C1 (en) 2013-09-27 2020-10-29 Genentech, Inc. Anti-PDL1 antibody formulations
US10414818B2 (en) 2013-09-27 2019-09-17 Roche Diagnostics Operations, Inc. Thermus thermophilus SlyD FKBP domain specific antibodies
EP3650023A1 (de) 2013-10-04 2020-05-13 Aptose Biosciences Inc. Zusammensetzungen zur behandlung von krebs
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
KR20160068855A (ko) 2013-10-11 2016-06-15 제넨테크, 인크. Nsp4 억제제 및 사용 방법
BR112016008477A2 (pt) 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
CN105849280B (zh) 2013-10-23 2020-11-06 豪夫迈·罗氏有限公司 诊断和治疗嗜酸性粒细胞紊乱的方法
EP3068892A4 (de) 2013-11-13 2017-05-31 Zymeworks Inc. Monovalente antigenbindende konstrukte zum targeting von egfr und/oder her2 und verwendungen davon
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
EP3074424A4 (de) 2013-11-27 2017-06-14 Zymeworks Inc. Gegen her2 gerichtete bispezifische antigenbindende konstrukte
NZ720769A (en) 2013-12-09 2022-10-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
WO2015089344A1 (en) 2013-12-13 2015-06-18 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
AU2014364601A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
MX2016007885A (es) 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
CN105899533B (zh) 2013-12-20 2019-10-11 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
RU2694981C2 (ru) 2014-01-03 2019-07-18 Ф. Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
CA2933384A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
KR102381685B1 (ko) 2014-01-06 2022-04-01 에프. 호프만-라 로슈 아게 1가 혈액 뇌 장벽 셔틀 모듈
SG11201605449YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
UA119863C2 (uk) 2014-01-24 2019-08-27 Нгм Біофармасьютікалс, Інк. Антитіло або його фрагмент, що зв'язується з бета-клото
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2016009515A (es) 2014-01-24 2016-10-26 Genentech Inc Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
JP6685912B2 (ja) 2014-02-08 2020-04-22 ジェネンテック, インコーポレイテッド アルツハイマー病治療方法
SG10201901076WA (en) 2014-02-08 2019-03-28 Genentech Inc Methods of treating alzheimer's disease
KR102030891B1 (ko) 2014-02-12 2019-10-11 제넨테크, 인크. 항-재기드1 항체 및 사용 방법
KR20160124165A (ko) 2014-02-21 2016-10-26 제넨테크, 인크. 항-il-13/il-17 이중특이적 항체 및 그의 용도
US10183996B2 (en) 2014-02-28 2019-01-22 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
AU2015229035B2 (en) 2014-03-14 2021-08-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック, インコーポレイテッド c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
RU2016136716A (ru) 2014-03-27 2018-04-28 Дженентек, Инк. Способы диагностики и лечения воспалительного заболевания кишечника
AU2015241037B2 (en) 2014-03-31 2020-10-15 Genentech, Inc. Anti-OX40 antibodies and methods of use
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
MX2016013635A (es) 2014-04-18 2017-02-02 Acceleron Pharma Inc Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
US20170044257A1 (en) 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
TN2016000459A1 (en) 2014-04-30 2018-04-04 Pfizer Cycloalkyl-linked diheterocycle derivatives.
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
RU2744836C2 (ru) 2014-05-08 2021-03-16 Новодиакс, Инк. Прямой иммуногистохимический анализ
EP3145952A2 (de) 2014-05-22 2017-03-29 Genentech, Inc. Anti-gpc3-antikörper und immunkonjugate
RU2016144405A (ru) 2014-05-23 2018-06-26 Дженентек, Инк. MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2015184004A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US11319567B2 (en) 2014-05-27 2022-05-03 Academia Sinica Fucosidase from bacteroides and methods using the same
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
CA2949982A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2015197736A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CN106574270B (zh) 2014-07-03 2021-07-13 豪夫迈·罗氏有限公司 多肽表达系统
EP3978524A1 (de) 2014-07-03 2022-04-06 Yale University Dickkopf2(dkk2)-inhibition zur unterdrückung der tumorbildung
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
JP6760919B2 (ja) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド 腫瘍を治療するための抗pd−l1組み合わせ
WO2016007235A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用cd33嵌合抗原受體治療癌症
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
PE20170263A1 (es) 2014-08-04 2017-03-30 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
MX2017001531A (es) 2014-08-08 2017-05-15 Alector Llc Anticuerpos anti-trem2 y metodos de uso de los mismos.
EP3180359A1 (de) 2014-08-14 2017-06-21 Novartis AG Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor
LT3183268T (lt) 2014-08-19 2020-06-10 Novartis Ag Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
KR20230172625A (ko) 2014-08-28 2023-12-22 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
CN114106185A (zh) 2014-09-12 2022-03-01 基因泰克公司 抗her2抗体和免疫缀合物
SG10201804931QA (en) 2014-09-12 2018-07-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
EP3191518B1 (de) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4-antikörper und immunkonjugate
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
SG11201701821QA (en) 2014-09-15 2017-04-27 Genentech Inc Antibody formulations
CN114621969A (zh) 2014-09-17 2022-06-14 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
EP3197500A1 (de) 2014-09-17 2017-08-02 Genentech, Inc. Immunkonjugate mit anti-her2-antikörpern und pyrrolobenzodiazepinen
AU2015320678B2 (en) 2014-09-23 2021-07-22 Genentech, Inc. Method of using anti-CD79b immunoconjugates
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Pd−l1に対する抗体分子およびその使用
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
EP3215850B1 (de) 2014-11-03 2019-07-03 F. Hoffmann-La Roche AG Tests zum nachweis von te-zell-immununtergruppen und verfahren zur verwendung davon
SG11201703521UA (en) 2014-11-03 2017-05-30 Genentech Inc Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
KR102544705B1 (ko) 2014-11-05 2023-06-15 제넨테크, 인크. 박테리아 내 2쇄 단백질을 생산하는 방법
KR20170080675A (ko) 2014-11-05 2017-07-10 제넨테크, 인크. 항-fgfr2/3 항체 및 이의 이용 방법
AU2015343029B2 (en) 2014-11-05 2021-07-29 Annexon, Inc. Humanized anti-complement factor C1q antibodies and uses thereof
WO2016073791A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
EP3552488A1 (de) 2014-11-10 2019-10-16 F. Hoffmann-La Roche AG Tiermodell für nephropathie und mittel zur behandlung davon
BR112017009728A2 (pt) 2014-11-10 2018-02-06 Genentech, Inc. anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
WO2016075278A1 (en) 2014-11-14 2016-05-19 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
CA2967368A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP2018501202A (ja) 2014-11-19 2018-01-18 ネステク ソシエテ アノニム セロトニン、トリプトファン、及びキヌレニンの代謝産物に対する抗体及びその使用
EP3845565A3 (de) 2014-11-19 2021-09-08 Genentech, Inc. Antikörper gegen bace1 und verwendung davon zur immuntherapie bei neuronalen erkrankungen
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
LT3789402T (lt) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
US20170269092A1 (en) 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
CA2966362A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Anti-cd79b antibodies and methods of use
BR112017011234A2 (pt) 2014-12-10 2018-03-27 Genentech Inc anticorpos contra receptor da barreira hematoencefálica e métodos de uso
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3233829B1 (de) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidin und triazinderivate und deren verwendung als axl-inhibitoren
EP3034130B1 (de) 2014-12-19 2019-12-04 Althia Health, S.L. Monoklonaler Antikörper zur Diagnose, Behandlung und/oder Prävention von Hirntumoren und Hirnverletzungen
EP3233921B1 (de) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anti-c5-antikörper und verfahren zur verwendung
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 2種以上の抗c5抗体の組み合わせおよび使用方法
CN107430127B (zh) 2015-01-24 2020-08-28 中央研究院 癌症标记及其使用方法
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3250927B1 (de) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Genexpressionsmarker und behandlung von multipler sklerose
JP6942633B2 (ja) 2015-01-30 2021-09-29 アカデミア シニカAcademia Sinica 抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CN107810192A (zh) 2015-02-23 2018-03-16 海鸥治疗简易股份公司 非天然的脑信号蛋白3及其医药用途
JP2018507868A (ja) 2015-02-26 2018-03-22 ジェネンテック, インコーポレイテッド インテグリンベータ7アンタゴニスト及びクローン病の治療方法
CA2978256A1 (en) 2015-03-06 2016-09-15 Genentech, Inc. Ultrapurified dsba and dsbc and methods of making and using the same
CN107430117A (zh) 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
EP3271401A4 (de) 2015-03-18 2018-11-21 Immunobiochem Corporation Gegen intrazelluläre tumorassoziierte antigene gerichtet konjugate zur behandlung von krebs
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EP3828199A1 (de) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Alk7: actriib-heteromultimere und verwendungen davon
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of using them
CN107709364A (zh) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
EP3611506B1 (de) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Vorhersage der therapeutischen reaktion auf alvocidib durch mitochondriales profilieren
JP6815331B2 (ja) 2015-04-21 2021-01-20 ジェネンテック, インコーポレイテッド 前立腺がんの分析のための組成物及び方法
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
PL3286315T3 (pl) 2015-04-24 2021-11-02 F. Hoffmann-La Roche Ag Sposoby identyfikacji bakterii zawierających polipeptydy wiążące
CN107709363A (zh) 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
EP3288957A4 (de) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. Nukleosidanaloga zur behandlung von viren der flaviviidae-familie und krebs
EP3936524A3 (de) 2015-05-11 2022-06-15 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur behandlung von lupus nephritis
MX2017014381A (es) 2015-05-12 2018-03-02 Genentech Inc Metodos terapeuticos y diagnosticos para cancer.
PL3298021T3 (pl) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Proleki alvocidibu o zwiększonej biodostępności
EP3795679A1 (de) 2015-05-28 2021-03-24 Genentech, Inc. Zellbasierter test zum nachweis von anti-cd3-homodimeren
ES2789500T5 (es) 2015-05-29 2023-09-20 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
WO2016196343A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use
AR105618A1 (es) 2015-05-29 2017-10-25 Genentech Inc Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
US20180153884A1 (en) 2015-05-31 2018-06-07 Curegenix Corporation Combination compositions for immunotherapy
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック, インコーポレイテッド 抗il−34抗体を使用して神経学的疾患を治療するための組成物及び方法
AU2016270858B2 (en) 2015-06-05 2022-04-28 Ac Immune Sa Anti-Tau antibodies and methods of use
JP2018518483A (ja) 2015-06-08 2018-07-12 ジェネンテック, インコーポレイテッド 抗ox40抗体及びpd−1軸結合アンタゴニストを使用して癌を治療する方法
JP2018521019A (ja) 2015-06-08 2018-08-02 ジェネンテック, インコーポレイテッド 抗ox40抗体を使用して癌を治療する方法
JP2018518491A (ja) 2015-06-12 2018-07-12 アレクトル エルエルシー 抗cd33抗体及びその使用方法
CN116063499A (zh) 2015-06-12 2023-05-05 艾利妥 抗cd33抗体及其使用方法
AR104987A1 (es) 2015-06-15 2017-08-30 Genentech Inc Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
EP3310811B1 (de) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3-antikörper und verfahren zur verwendung
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
WO2016205520A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Humanized and affinity matured antibodies to fcrh5 and methods of use
AU2016278239B9 (en) 2015-06-17 2022-08-11 Allakos Inc. Methods and compositions for treating fibrotic diseases
AU2016280159A1 (en) 2015-06-17 2017-12-07 Genentech, Inc. Anti-HER2 antibodies and methods of use
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
AR105089A1 (es) 2015-06-24 2017-09-06 Hoffmann La Roche ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
MX2017016645A (es) 2015-06-29 2018-11-09 Genentech Inc Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
CA3162586A1 (en) 2015-06-29 2017-01-05 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3316902A1 (de) 2015-07-29 2018-05-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
EP4218792A1 (de) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Zusammensetzung zur behandlung von myeloproliferativen erkrankungen
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
MX2018001566A (es) 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
EP3932953A1 (de) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anti-hypusin-antikörper und verwendungen davon
WO2017041027A1 (en) 2015-09-04 2017-03-09 Obi Pharma, Inc. Glycan arrays and method of use
EP3328885A1 (de) 2015-09-11 2018-06-06 Bruce Andrien Rekombinantes glykosyliertes eculizumab und eculizumabvarianten
CN108271372B (zh) 2015-09-18 2021-07-09 中外制药株式会社 Il-8-结合抗体及其应用
EP3353206A1 (de) 2015-09-22 2018-08-01 Spring Bioscience Corporation Anti-ox40-antikörper und diagnostische verwendungen davon
BR112018005737A2 (pt) 2015-09-23 2018-10-09 Genentech Inc anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
WO2017058881A1 (en) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
AU2016329120B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory TNF receptor
EP3356407B1 (de) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispezifische anti-cd19xcd3-t-zell-aktivierende antigenbindende moleküle
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
JP6654694B2 (ja) 2015-10-02 2020-02-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗pd1抗体と使用方法
US20170096485A1 (en) 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
CN107949574A (zh) 2015-10-02 2018-04-20 豪夫迈·罗氏有限公司 双特异性t细胞活化性抗原结合分子
WO2017055389A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
JP2018529747A (ja) 2015-10-06 2018-10-11 ジェネンテック, インコーポレイテッド 多発性硬化症を治療するための方法
WO2017062672A2 (en) 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR20180054877A (ko) 2015-10-07 2018-05-24 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 대해 4가를 갖는 이중특이적 항체
WO2017062649A1 (en) 2015-10-07 2017-04-13 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
WO2017070554A1 (en) 2015-10-23 2017-04-27 Fred Hutchinson Cancer Research Center Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
RU2018119317A (ru) 2015-10-28 2019-12-04 Йейл Юниверсити Гуманизированное антитело к dkk2 и его применение
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
SG11201803567XA (en) 2015-10-29 2018-05-30 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
CA3000048A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
AU2016344399B2 (en) 2015-10-30 2019-03-28 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
EP3371217A1 (de) 2015-11-08 2018-09-12 H. Hoffnabb-La Roche Ag Screening-verfahren für multispezifische antikörper
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
CN108601752A (zh) 2015-12-03 2018-09-28 安吉奥斯医药品有限公司 用于治疗mtap缺失型癌症的mat2a抑制剂
MX2018005229A (es) 2015-12-09 2019-04-29 F Hoffmann­La Roche Ag Anticuerpo anti-cd20 de tipo ii y usos del mismo.
EP3178848A1 (de) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
EP3390441B1 (de) 2015-12-15 2021-08-25 Gilead Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus
EP3389713A2 (de) 2015-12-17 2018-10-24 Novartis AG Kombination von c-met-inhibitor mit antikörpermolekül zu pd-1 und verwendungen davon
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
CN108401431B (zh) 2015-12-18 2022-01-25 中外制药株式会社 抗-c5抗体及使用方法
JP7008023B2 (ja) 2015-12-30 2022-01-25 ジェネンテック, インコーポレイテッド 低減されたポリソルベート分解を有する製剤
JP7046814B2 (ja) 2015-12-30 2022-04-04 ジェネンテック, インコーポレイテッド タンパク質製剤のためのトリプトファン誘導体の使用
WO2017118307A1 (zh) 2016-01-05 2017-07-13 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
CN108368179B (zh) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
CA3011739A1 (en) 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
ES2847155T3 (es) 2016-01-21 2021-08-02 Novartis Ag Moléculas multiespecíficas que fijan como objetivo CLL-1
WO2017132279A1 (en) 2016-01-25 2017-08-03 Genentech, Inc. Methods for assaying t-cell dependent bispecific antibodies
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス,インコーポレイテッド 突然変異体スムースンド及びその使用方法
US10982136B2 (en) 2016-02-26 2021-04-20 The Regents Of The University Of California Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
CA3015528A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3423493A2 (de) 2016-03-04 2019-01-09 Alector LLC Anti-trem1-antikörper und verfahren zur verwendung davon
EP3216458A1 (de) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
AU2017235097B2 (en) 2016-03-15 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
DK3433280T3 (da) 2016-03-22 2023-06-19 Hoffmann La Roche Protease-aktiverede T-celle-bispecifikke molekyler
SG11201808085WA (en) 2016-03-22 2018-10-30 Hoffmann La Roche Protease-activated t cell bispecific molecules
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3231813A1 (de) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
CN109311995A (zh) 2016-03-29 2019-02-05 台湾浩鼎生技股份有限公司 抗体、药物组合物和方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
JP2019515670A (ja) 2016-04-15 2019-06-13 ジェネンテック, インコーポレイテッド がんをモニタリングし治療するための方法
ES2944607T3 (es) 2016-04-15 2023-06-22 Novartis Ag Composiciones y métodos para la expresión selectiva de receptores quiméricos para el antígeno
SG11201808994YA (en) 2016-04-15 2018-11-29 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
PL3443350T3 (pl) 2016-04-15 2021-05-31 F. Hoffmann-La Roche Ag Sposoby monitorowania i leczenia nowotworu
TWI697333B (zh) 2016-04-22 2020-07-01 台灣浩鼎生技股份有限公司 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法
PE20181890A1 (es) 2016-05-02 2018-12-11 Hoffmann La Roche Contorsbody - un ligante de diana monocatenario
EP3454863A1 (de) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationstherapien zur behandlung von krebs
EP3243836A1 (de) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
JP7285076B2 (ja) 2016-05-11 2023-06-01 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Tnfファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
SI3455261T1 (sl) 2016-05-13 2023-01-31 Bioatla, Inc. Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
EP3243832A1 (de) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
EP3458608A1 (de) 2016-05-17 2019-03-27 H. Hoffnabb-La Roche Ag Stromagensignaturen zur diagnose und verwendung in der immuntherapie
EP3458101B1 (de) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac-antikörper-konjugate und verfahren zur verwendung
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
EP3252078A1 (de) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
EP3464375A2 (de) 2016-06-02 2019-04-10 Novartis AG Therapeutische schemata für chimäre antigenrezeptor(car)-exprimierende zellen
EP3464354B1 (de) 2016-06-02 2021-07-28 Bloom Diagnostics AG Antikörper zur bindung an humane anti-müller-hormone (amh) und deren verwendungen
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2017218977A2 (en) 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
CN116143918A (zh) 2016-06-24 2023-05-23 豪夫迈·罗氏有限公司 抗聚泛素多特异性抗体
WO2018011691A1 (en) 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
AU2017297603A1 (en) 2016-07-14 2019-02-14 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
US10722558B2 (en) 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
WO2018013918A2 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
MA45811A (fr) 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
CA3032049C (en) 2016-07-27 2023-11-07 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR20230100748A (ko) 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
CN110062767B (zh) 2016-07-29 2023-07-11 台湾浩鼎生技股份有限公司 人抗体、药物组合物和方法
KR20190036551A (ko) 2016-08-01 2019-04-04 노파르티스 아게 Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN115598231A (zh) 2016-08-15 2023-01-13 豪夫迈·罗氏有限公司(Ch) 定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
US11235076B2 (en) 2016-08-29 2022-02-01 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides
WO2018043311A1 (ja) 2016-08-31 2018-03-08 オンコセラピー・サイエンス株式会社 Melkに対するモノクローナル抗体およびその使用
JP7018210B2 (ja) 2016-09-06 2022-02-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒドロキシピリドネートアクチニド/ランタニド体外除去剤の製剤
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CA3036701A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
JP6976315B2 (ja) 2016-09-19 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 補体因子に基づくアフィニティークロマトグラフィー
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
PT3528838T (pt) 2016-09-23 2023-09-04 Hoffmann La Roche Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
EP3519437B1 (de) 2016-09-30 2021-09-08 F. Hoffmann-La Roche AG Bispezifiche antikörper gegen p95her2
EP3522933B1 (de) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Verfahren zur herstellung von antikörperarzneimittelkonjugaten
CN110198743B (zh) 2016-10-05 2023-07-18 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
EP3523451A1 (de) 2016-10-06 2019-08-14 Genentech, Inc. Therapeutische und diagnostische verfahren für krebs
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對fzd10之單株抗體及其用途
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
JP7096240B2 (ja) 2016-10-19 2022-07-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 試料中の非結合c5の定量化方法
US11828683B2 (en) 2016-10-19 2023-11-28 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5a in a sample
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
CN110267678A (zh) 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法
US11466094B2 (en) 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
US11000601B2 (en) 2016-11-21 2021-05-11 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
SG10201911351SA (en) 2016-12-07 2020-02-27 Genentech Inc Anti-tau antibodies and methods of use
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック, インコーポレイテッド 抗tau抗体及び使用方法
JP7141407B2 (ja) 2016-12-13 2022-09-22 エフ.ホフマン-ラ ロシュ アーゲー 腫瘍試料における標的抗原の存在を決定する方法
AU2017380981A1 (en) 2016-12-19 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1BB (CD137) agonists
EP3362471B1 (de) 2016-12-19 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Profilierung von peptiden und verfahren zur sensitivitätsprofilierung
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2018127473A1 (en) 2017-01-03 2018-07-12 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met抗體以及其免疫結合物及用途
CN110709419B (zh) 2017-01-06 2023-11-28 博奥信生物技术(南京)有限公司 Erbb2抗体及其用途
EP4043485A1 (de) 2017-01-26 2022-08-17 Novartis AG Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
TWI778018B (zh) 2017-02-10 2022-09-21 美商建南德克公司 抗類胰蛋白酶抗體、其組合物及其用途
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
JP7116736B2 (ja) 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗cxcr5抗體治療狼瘡
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CR20190481A (es) 2017-03-22 2020-01-06 Genentech Inc Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares
AU2018241625A1 (en) 2017-03-27 2019-09-05 F. Hoffmann-La Roche Ag Improved antigen binding receptor formats
JP2020515256A (ja) 2017-03-27 2020-05-28 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 改良された抗原結合受容体
SG10201911225WA (en) 2017-03-28 2020-01-30 Genentech Inc Methods of treating neurodegenerative diseases
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
EP3601345A1 (de) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
JP7205995B2 (ja) 2017-03-29 2023-01-17 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 共刺激性tnf受容体に対する二重特異性抗原結合分子
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN110494452B (zh) 2017-04-03 2023-08-25 豪夫迈·罗氏有限公司 结合steap-1的抗体
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
PE20191494A1 (es) 2017-04-03 2019-10-21 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
CN110402255B (zh) 2017-04-04 2022-12-02 豪夫迈·罗氏有限公司 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
EP3606955A1 (de) 2017-04-05 2020-02-12 H. Hoffnabb-La Roche Ag Bispezifische antikörper mit spezifischer bindung an pd1 und lag3
DK3606954T3 (en) 2017-04-05 2022-09-26 Hoffmann La Roche Anti-LAG3-antistoffer
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
CN108728444A (zh) 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 免疫调节性多核苷酸及其应用
TW201841656A (zh) 2017-04-21 2018-12-01 美商建南德克公司 Klk5拮抗劑用於治療疾病之用途
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CA3062415A1 (en) 2017-05-05 2018-11-08 Christopher Robert Bebbington Methods and compositions for treating allergic ocular diseases
EP3625251A1 (de) 2017-05-15 2020-03-25 University Of Rochester Breit neutralisierende monoklonale anti-influenza-antikörper und verwendungen davon
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
EP3409322A1 (de) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Behandlungsverfahren
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
EP3645037A1 (de) 2017-06-27 2020-05-06 Novartis AG Dosierungsschema für anti-tim-3-antikörper und verwendungen davon
MA49565A (fr) 2017-07-11 2020-05-20 Compass Therapeutics Llc Anticorps agonistes qui lient cd137 humain et leurs utilisations
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
JP2020527351A (ja) 2017-07-21 2020-09-10 ジェネンテック, インコーポレイテッド がんの治療法及び診断法
CA3071193A1 (en) 2017-07-26 2019-01-31 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
WO2019020745A1 (en) 2017-07-28 2019-01-31 F. Hoffmann-La Roche Ag BISPECIFIC ANTIBODY FORMULATION
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
MA47691A (fr) 2017-08-03 2020-01-08 Alector Llc Anticorps anti-cd33 et leurs procédés d'utilisation
EP3665197A2 (de) 2017-08-11 2020-06-17 H. Hoffnabb-La Roche Ag Anti-cd8-antikörper und verwendungen davon
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー, インコーポレイテッド Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
SG10202007194PA (en) 2017-09-29 2020-08-28 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
WO2019077092A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
EP3704145A1 (de) 2017-10-30 2020-09-09 F. Hoffmann-La Roche AG Verfahren zur in-vivo-erzeugung multispezifischer antikörper aus monospezifischen antikörpern
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
MA50505A (fr) 2017-11-01 2020-09-09 Hoffmann La Roche Anticorps 2 + 1 bispécifiques (contorsbodies)
EP3704150A1 (de) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Compbody ein multivalentes zielbindemittel
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
JP7092881B2 (ja) 2017-11-01 2022-06-28 エフ.ホフマン-ラ ロシュ アーゲー TriFabコントースボディ
WO2019086497A2 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Combination therapy with targeted ox40 agonists
MX2020004567A (es) 2017-11-06 2020-08-13 Genentech Inc Metodos diagnosticos y terapeuticos para el cancer.
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
KR20200099135A (ko) 2017-12-14 2020-08-21 에프. 호프만-라 로슈 아게 Cea cd3 이중특이성 항체 및 pd-1 축 결합 길항제의 암 치료를 위한 투약 요법에서의 용도
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
CN111247429A (zh) 2017-12-21 2020-06-05 豪夫迈·罗氏有限公司 用于新颖抗原结合模块的特异性测试的通用报告细胞测定法
JP2021508246A (ja) 2017-12-21 2021-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規抗原結合部分の特異性試験のためのcar−t細胞アッセイ
EP3502140A1 (de) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
EP3728321A1 (de) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Verwendung von pilra-bindenden mitteln zur behandlung einer erkrankung
CN111542543B (zh) 2017-12-28 2023-12-22 南京传奇生物科技有限公司 针对pd-l1的抗体及其变体
JP7369127B2 (ja) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー,リミテッド Tigitに対する単一ドメイン抗体及びその変異体
WO2019133512A1 (en) 2017-12-29 2019-07-04 Alector Llc Anti-tmem106b antibodies and methods of use thereof
EP3731865A1 (de) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Verfahren zur verbesserung der vegf-rezeptor-blockierenden selektivität eines anti-vegf-antikörpers
WO2019137541A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
US20200339686A1 (en) 2018-01-16 2020-10-29 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CN111655730A (zh) 2018-01-31 2020-09-11 豪夫迈·罗氏有限公司 包含与lag3结合的抗原结合位点的双特异性抗体
EP3746116A1 (de) 2018-01-31 2020-12-09 Novartis AG Kombinationstherapie unter verwendung eines chimären antigenrezeptors
WO2019149715A1 (en) 2018-01-31 2019-08-08 F. Hoffmann-La Roche Ag Stabilized immunoglobulin domains
MA51793A (fr) 2018-02-08 2020-12-16 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
EP3749362A1 (de) 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutische und diagnostische verfahren für mastzellvermittelte entzündliche erkrankungen
CR20200341A (es) 2018-02-09 2020-11-02 Hoffmann La Roche Anticuerpos de unión a gprc5d
TW202000702A (zh) 2018-02-26 2020-01-01 美商建南德克公司 用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
CN111742219A (zh) 2018-03-01 2020-10-02 豪夫迈·罗氏有限公司 用于新颖靶抗原结合模块的特异性测定法
TW202003561A (zh) 2018-03-13 2020-01-16 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
WO2019175071A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
SG11202006217YA (en) 2018-03-14 2020-07-29 Beijing Xuanyi Pharmasciences Co Ltd Anti-claudin 18.2 antibodies
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
RU2020134294A (ru) 2018-03-21 2022-04-22 ЭйЭлЭкс Онколоджи Инк. Антитела против сигнал-регуляторного белка альфа и способы их применения
KR20230042407A (ko) 2018-03-29 2023-03-28 제넨테크, 인크. 포유류 세포들에서 젖분비자극 활성의 조절
US11840568B2 (en) 2018-04-02 2023-12-12 Mab-Venture Biopharm Co., Ltd. Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof
JP7394067B2 (ja) 2018-04-04 2023-12-07 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がん患者における腫瘍抗原を検出するための診断アッセイ
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
CN112424601A (zh) 2018-04-04 2021-02-26 豪夫迈·罗氏有限公司 检测癌症患者中肿瘤抗原的诊断性测定法
EP3774883A1 (de) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antikörper und fragmente davon, die hepatitis-b-virus-protein x binden
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CA3094235A1 (en) 2018-04-13 2019-10-17 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1bbl
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788071A1 (de) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose, prävention und behandlung von epstein-barr-virusinfektion
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
MX2020012248A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
AU2019271148B2 (en) 2018-05-14 2023-07-06 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CN112166196A (zh) 2018-05-18 2021-01-01 豪夫迈·罗氏有限公司 大核酸的靶向细胞内递送
US20200109195A1 (en) 2018-05-21 2020-04-09 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
BR112020023844A2 (pt) 2018-05-25 2021-04-13 Alector Llc Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3805400A4 (de) 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit veränderter halbwertszeit im cytoplasma
CN112512638A (zh) 2018-06-08 2021-03-16 艾利妥 抗siglec-7抗体及其使用方法
TW202016139A (zh) 2018-06-13 2020-05-01 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
JP2021528996A (ja) 2018-06-19 2021-10-28 アターガ,エルエルシー 補体第5成分に対する抗体分子およびその使用
MX2020014091A (es) 2018-06-23 2021-05-27 Genentech Inc Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii.
TW202035444A (zh) 2018-06-27 2020-10-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
WO2020006374A2 (en) 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
CN112424228A (zh) 2018-07-04 2021-02-26 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PL3618928T3 (pl) 2018-07-13 2023-05-02 Alector Llc Przeciwciała antysortylinowe i sposoby ich stosowania
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
BR112021000727A2 (pt) 2018-07-20 2021-04-13 Surface Oncology, Inc. Composições anti-cd112r e métodos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
JP2021530554A (ja) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド 異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤
BR112021001451A2 (pt) 2018-07-27 2021-04-27 Alector Llc anticorpos monoclonais anti-siglec-5 isolados, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, composição farmacêutica e métodos para induzir ou promover a sobrevida, para diminuir a atividade, para diminuir os níveis celulares, para induzir a produção de espécies reativas, para induzir a formação de neutrophil extracellular trap (net), para induzir a ativação de neutrófilos, para atenuar um ou mais neutrófilos imunossuprimidos e para aumentar a atividade de fagocitose
SG11202101152QA (en) 2018-08-03 2021-03-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other
KR20210042936A (ko) 2018-08-08 2021-04-20 제넨테크, 인크. 단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도
AR114550A1 (es) 2018-08-10 2020-09-16 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno anti-cd137 y sus usos
TW202021618A (zh) 2018-08-17 2020-06-16 美商23與我有限公司 抗il1rap抗體及其使用方法
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
CN113801229A (zh) 2018-08-31 2021-12-17 艾利妥 抗cd33抗体及其使用方法
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AR114732A1 (es) 2018-09-18 2020-10-07 Hoffmann La Roche Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
WO2020061060A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
MX2021003213A (es) 2018-09-21 2021-05-12 Genentech Inc Metodos de diagnostico para cancer de mama triple negativo.
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
EP3856773A1 (de) 2018-09-28 2021-08-04 Kyowa Kirin Co., Ltd. Il-36-antikörper und verwendungen davon
EP3861025A1 (de) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispezifische antigenbindende moleküle mit dreiwertiger bindung an cd40
CN112955468A (zh) 2018-10-01 2021-06-11 豪夫迈·罗氏有限公司 包含抗fap克隆212的双特异性抗原结合分子
US20200109200A1 (en) 2018-10-09 2020-04-09 Genentech, Inc. Methods and systems for determining synapse formation
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
EP3870235A1 (de) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Konjugierte chemische abbauauslöser und verwendungsverfahren
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
SG11202104104VA (en) 2018-11-05 2021-05-28 Genentech Inc Methods of producing two chain proteins in prokaryotic host cells
WO2020102387A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2020104705A2 (en) 2018-11-23 2020-05-28 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
AU2019391097A1 (en) 2018-12-04 2021-05-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック, インコーポレイテッド Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.
JP2022514903A (ja) 2018-12-20 2022-02-16 協和キリン株式会社 Fn14抗体及びその使用
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020127618A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
WO2020127628A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted superagonistic cd28 antigen binding molecules
KR20210107721A (ko) 2018-12-21 2021-09-01 23앤드미 인코포레이티드 항-il-36 항체 및 이의 사용 방법
JP2022514082A (ja) 2018-12-21 2022-02-09 ジェネンテック, インコーポレイテッド アポトーシスに耐性のある細胞株を使用してポリペプチドを生成する方法
BR112021011939A2 (pt) 2018-12-21 2021-09-14 F. Hoffmann-La Roche Ag Anticorpo que se liga a cd3, anticorpos que se ligam a cd3 e tyrp-1, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo que se liga a cd3, composição farmacêutica e usos do anticorpo
JP2022516881A (ja) 2018-12-26 2022-03-03 キシリオ ディベロップメント インコーポレイテッド 抗ctla4抗体およびその使用方法
CN113272327A (zh) 2018-12-30 2021-08-17 豪夫迈·罗氏有限公司 抗兔cd19抗体及其使用方法
CN115120716A (zh) 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
JP2022520811A (ja) 2019-02-15 2022-04-01 ノバルティス アーゲー 3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
KR20210129672A (ko) 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
WO2020169698A1 (en) 2019-02-21 2020-08-27 F. Hoffmann-La Roche Ag Sensitization of cancer cells to tnf by bet inhibition
EP3927371A1 (de) 2019-02-22 2021-12-29 Novartis AG Kombinationstherapien von chimären egfrviii-antigenrezeptoren und pd-1-inhibitoren
AU2020228383A1 (en) 2019-02-27 2021-09-23 Genentech, Inc. Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
TW202101000A (zh) 2019-03-08 2021-01-01 美商建南德克公司 用於偵測且量化膜相關蛋白之方法
CN113518923A (zh) 2019-03-13 2021-10-19 默克专利股份公司 用于脂质化蛋白质结构的制备的方法
JP2022524074A (ja) 2019-03-14 2022-04-27 ジェネンテック, インコーポレイテッド 抗HER2 MABと組み合わせたHER2xCD3二重特異性抗体によるがんの処置
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
JP2022519923A (ja) 2019-03-22 2022-03-25 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
AU2020253833A1 (en) 2019-03-29 2021-10-28 Atarga, Llc Anti FGF23 antibody
EP3953386A1 (de) 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Behandlung von krebs mit einem cea-cd3-bispezifischen antikörper und einem wnt-signalinhibitor
CN113677403A (zh) 2019-04-12 2021-11-19 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
WO2020213724A1 (ja) 2019-04-19 2020-10-22 中外製薬株式会社 抗体改変部位認識キメラ受容体
CN114364703A (zh) 2019-04-19 2022-04-15 豪夫迈·罗氏有限公司 抗mertk抗体及它们的使用方法
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
MX2021013222A (es) 2019-05-03 2022-01-06 Genentech Inc Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
KR20220006519A (ko) 2019-05-10 2022-01-17 다케다 야쿠힌 고교 가부시키가이샤 항체 약물 접합체
CA3137512A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
TW202108178A (zh) 2019-05-14 2021-03-01 美商建南德克公司 使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
EP3969906A1 (de) 2019-05-16 2022-03-23 ProciseDx Inc. Assay-nachweisverfahren für vcam-1 und calprotectin
EP3821250B1 (de) 2019-05-16 2022-05-04 ProciseDx Inc. Testverfahren zum nachweis von vcam-1 und alpha-2-makroglobulin in blut
EP3973290A1 (de) 2019-05-23 2022-03-30 ProciseDx Inc. Testverfahren zum nachweis von humanem serumalbumin, vitamin d, c-reaktivem protein und anti-transglutaminase-antikörper
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
EP3980779A1 (de) 2019-06-06 2022-04-13 ProciseDx Inc. Nachweis von hämoglobin a1c (hba1c) in blut
US20200392229A1 (en) 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
JP2022540764A (ja) 2019-06-25 2022-09-20 プロサイセデクス インコーポレイティド 抗TNFα生物製剤および抗薬剤抗体の検出
WO2020260329A1 (en) 2019-06-26 2020-12-30 F. Hoffmann-La Roche Ag Fusion of an antibody binding cea and 4-1bbl
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規icos抗体及びそれらを含む腫瘍標的化抗原結合分子
MX2021015694A (es) 2019-06-28 2022-03-11 Genentech Inc Composición y métodos para estabilizar formulaciones líquidas de proteínas.
CN114051500A (zh) 2019-07-02 2022-02-15 豪夫迈·罗氏有限公司 包含白细胞介素-2突变体和抗cd8抗体的免疫缀合物
EP3998083A4 (de) 2019-07-12 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antikörper gegen mutationstyp fgfr3 und verwendung davon
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
EP4004051A4 (de) 2019-07-19 2023-08-23 Oncoresponse, Inc. Immunmodulatorische antikörper und verfahren zur verwendung davon
CN114341181A (zh) 2019-07-31 2022-04-12 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
CR20220019A (es) 2019-07-31 2022-02-11 Hoffmann La Roche Anticuerpos que se fijan a gprc5d
JP2022543551A (ja) 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Gprc5dに結合する抗体
MX2022002963A (es) 2019-09-12 2022-04-06 Genentech Inc Composiciones y metodos para tratar nefritis lupica.
CA3150999A1 (en) 2019-09-18 2021-03-25 James Thomas Koerber Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CR20220149A (es) 2019-09-20 2022-05-23 Genentech Inc Dosis para anticuerpos anti-triptasa
CN114829401A (zh) 2019-09-27 2022-07-29 南京金斯瑞生物科技有限公司 抗vhh域抗体及其用途
CA3151406A1 (en) 2019-09-27 2021-04-01 Raymond D. Meng Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TW202122114A (zh) 2019-10-18 2021-06-16 美商建南德克公司 使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
CA3157665A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination treatments with ventoclax and tim-3 inhibitors
CA3155308A1 (en) 2019-11-05 2021-05-14 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide
IL292458A (en) 2019-11-06 2022-06-01 Genentech Inc Diagnostic and treatment methods for the treatment of hematological cancer
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
CN115003699A (zh) 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
BR112022011337A2 (pt) 2019-12-12 2022-08-23 Alector Llc Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
CR20230210A (es) 2019-12-13 2023-06-14 Genentech Inc ANTICUERPOS ANTI-LY6G6D Y MÉTODOS DE USO (Divisional 2022-0330)
BR112022011570A2 (pt) 2019-12-13 2022-12-13 Alector Llc Anticorpos anti-mertk e métodos de uso dos mesmos
EP4076666A1 (de) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG An hla-a2/mage-a4 bindende antikörper
KR20220116522A (ko) 2019-12-20 2022-08-23 노파르티스 아게 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도
IL294131A (en) 2019-12-23 2022-08-01 Genentech Inc Antibodies specific for apolipoprotein l1 and methods of use
MX2022007840A (es) 2019-12-27 2022-07-19 Chugai Pharmaceutical Co Ltd Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla4) y uso del mismo.
WO2021140130A1 (en) 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag New 4-1bbl trimer-containing antigen binding molecules
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021146636A1 (en) 2020-01-17 2021-07-22 Becton, Dickinson And Company Methods and compositions for single cell secretomics
EP4090335A1 (de) 2020-01-17 2022-11-23 Novartis AG Kombination aus einem tim-3-inhibitor und einem hypomethylierungsmittel zur verwendung bei der behandlung von myelodysplastischem syndrom oder chronischer myelomonozytischer leukämie
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN115768800A (zh) 2020-01-31 2023-03-07 克利夫兰诊所基金会 抗苗勒管激素受体2抗体和使用方法
AU2021212197A1 (en) 2020-01-31 2022-08-04 BioNTech SE Methods of inducing neoepitope-specific T cells with a PD-1 axis binding antagonist and an RNA vaccine
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
AU2021218927A1 (en) 2020-02-10 2022-09-22 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
CN115427453A (zh) 2020-02-10 2022-12-02 上海诗健生物科技有限公司 Cldn18.2抗体及其用途
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
MX2022010685A (es) 2020-02-27 2022-09-23 Novartis Ag Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
KR20220152262A (ko) 2020-03-13 2022-11-15 제넨테크, 인크. 항-인터루킨-33 항체 및 이의 용도
CA3169626A1 (en) 2020-03-19 2021-09-23 Genentech, Inc. Isoform-selective anti-tgf-beta antibodies and methods of use
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
JP2023519213A (ja) 2020-03-24 2023-05-10 ジェネンテック, インコーポレイテッド Tie2結合剤および使用方法
US20210309989A1 (en) 2020-03-26 2021-10-07 Genentech, Inc. Modified mammalian cells
IL296802A (en) 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd A method for the production of multispecific antigen binding molecules
CN116075525A (zh) 2020-03-31 2023-05-05 艾莱克特有限责任公司 抗mertk抗体及其使用方法
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
JP2023519930A (ja) 2020-04-01 2023-05-15 ユニバーシティ オブ ロチェスター インフルエンザh3n2ウイルスのヘマグルチニン(ha)およびノイラミニダーゼ(na)に対するモノクローナル抗体
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US20230183341A1 (en) 2020-04-03 2023-06-15 Alector Llc Methods of use of anti-trem2 antibodies
AU2021252156A1 (en) 2020-04-09 2022-11-03 Technische Universität München Targeted delivery of an inhibitor of miR-21 to macrophages for the treatment of pulmonary fibrosis
CA3180222A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
BR112022020629A2 (pt) 2020-04-15 2022-11-29 Hoffmann La Roche Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
TW202206111A (zh) 2020-04-24 2022-02-16 美商建南德克公司 使用抗cd79b免疫結合物之方法
PE20230078A1 (es) 2020-04-24 2023-01-11 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados
JP2023523145A (ja) 2020-04-27 2023-06-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リポ蛋白(a)に対するイソ型非依存性抗体
EP4143345A1 (de) 2020-04-28 2023-03-08 Genentech, Inc. Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
SG11202112792WA (en) 2020-04-28 2021-12-30 Univ Rockefeller Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2021222533A1 (en) 2020-04-30 2021-11-04 Procisedx Inc. Methods of detecting antibodies to sars-cov-2
IL297830A (en) 2020-05-03 2023-01-01 Levena Suzhou Biopharma Co Ltd Anti-drug compounds (adcs) comprising an anti-trop-2 antibody, compounds comprising such adcs, as well as methods for their production and use
US20230212260A1 (en) 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
MX2022014736A (es) 2020-05-29 2023-03-23 23Andme Inc Anticuerpos anti-cd200r1 y metodos de uso de estos.
CR20220659A (es) 2020-06-08 2023-08-21 Hoffmann La Roche Anticuerpos anti-hbv y metodos de uso
KR20230023727A (ko) 2020-06-11 2023-02-17 제넨테크, 인크. 나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법
JP2023529206A (ja) 2020-06-12 2023-07-07 ジェネンテック, インコーポレイテッド がん免疫療法のための方法及び組成物
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and preparations for the treatment of triple-negative breast cancer
CA3181672A1 (en) 2020-06-18 2021-12-23 Shi Li Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
BR112022025809A2 (pt) 2020-06-19 2023-01-10 Hoffmann La Roche Anticorpos, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo, uso do anticorpo, método para tratar uma doença e invenção
TW202214704A (zh) 2020-06-19 2022-04-16 瑞士商赫孚孟拉羅股份公司 蛋白酶活化t細胞雙特異性抗體
CR20220628A (es) 2020-06-19 2023-01-24 Hoffmann La Roche Anticuerpos que se unen a cd3
PE20231080A1 (es) 2020-06-19 2023-07-17 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
JP2023531222A (ja) 2020-06-22 2023-07-21 アルミラル・ソシエダッド・アノニマ 抗il-36抗体およびその使用方法
CN115702168A (zh) 2020-06-23 2023-02-14 豪夫迈·罗氏有限公司 靶向Her2的激动性CD28抗原结合分子
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
IL299161A (en) 2020-06-24 2023-02-01 Genentech Inc Cell lines resistant to apoptosis
JP2023531067A (ja) 2020-06-25 2023-07-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗cd3/抗cd28二重特異性抗原結合分子
JP2023533533A (ja) 2020-07-10 2023-08-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、当該細胞に対して放射性ヌクレオチドを標的化する抗体
CN115812149A (zh) 2020-07-13 2023-03-17 基因泰克公司 用于预测多肽免疫原性的基于细胞的方法
US11524998B2 (en) 2020-07-16 2022-12-13 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
AU2021308653A1 (en) 2020-07-17 2023-02-16 Genentech, Inc. Anti-Notch2 antibodies and methods of use
TW202216215A (zh) 2020-07-21 2022-05-01 美商建南德克公司 Brm降解之抗體結合化學誘導物及其方法
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CN115836122A (zh) 2020-08-07 2023-03-21 基因泰克公司 用于预测多肽免疫原性的基于t细胞的方法
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之CRISPR/Cas9多重剔除
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20220089754A1 (en) 2020-09-14 2022-03-24 Ichnos Sciences SA Antibodies that bind to il1rap and uses thereof
CA3193478A1 (en) 2020-09-24 2022-03-31 F. Hoffmann-La Roche Ag Prevention or mitigation of t-cell bispecific antibody-related adverse effects
CN116406291A (zh) 2020-10-05 2023-07-07 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
TW202233671A (zh) 2020-10-20 2022-09-01 美商建南德克公司 Peg結合抗mertk抗體及其使用方法
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
IL302277A (en) 2020-10-22 2023-06-01 Janssen Biotech Inc Proteins containing delta-like ligand antigen binding domains (DLL3) and uses thereof
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
JP2023549062A (ja) 2020-10-30 2023-11-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト CEA CD3二重特異性抗体及びTGFβシグナル伝達阻害剤を使用したがんの治療
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021374594A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
AU2021374590A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
EP4240765A2 (de) 2020-11-06 2023-09-13 Novartis AG Antikörper-fc-varianten
TW202233248A (zh) 2020-11-08 2022-09-01 美商西健公司 組合療法
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
CA3196810A1 (en) 2020-11-10 2022-05-19 F. Hoffmann-La Roche Ag Prevention or mitigation of t-cell engaging agent-related adverse effects
EP4243857A1 (de) 2020-11-13 2023-09-20 Novartis AG Kombinationstherapien mit zellen zur expression des chimären antigenrezeptors (car)
WO2022101088A1 (en) 2020-11-16 2022-05-19 F. Hoffmann-La Roche Ag Fab high mannose glycoforms
EP4244254A1 (de) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Kombinationstherapie mit fap-gerichteten cd40-agonisten
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
IL303381A (en) 2020-12-04 2023-08-01 Hoffmann La Roche PH-dependent mutant interleukin-2 polypeptides
AU2021395729A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
AU2021398385A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Antibodies against interleukin-22
CA3204702A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ, インコーポレイテッド 高親和性及び/または特異性を有する結合剤分子ならびにその製造及び使用方法
AU2022206061A1 (en) 2021-01-06 2023-07-06 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
JP2024504931A (ja) 2021-01-12 2024-02-02 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体
WO2022152701A1 (en) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Combination therapy
WO2022155324A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
AU2022210221A1 (en) 2021-01-20 2023-08-31 Oncoresponse, Inc. Immunomodulatory antibodies and uses thereof
CN116917326A (zh) 2021-01-22 2023-10-20 博泰康医药公司 抗her-2/trop-2构建体及其用途
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗cd73及び抗entpd2抗体のための投与方式並びにその使用
CA3209364A1 (en) 2021-03-01 2022-09-09 Jennifer O'neil Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022187270A1 (en) 2021-03-01 2022-09-09 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CN117440832A (zh) 2021-03-03 2024-01-23 索伦托药业有限公司 包括抗bcma抗体的抗体-药物缀合物
CN117062839A (zh) 2021-03-12 2023-11-14 基因泰克公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
AU2022238526A1 (en) 2021-03-15 2023-09-07 F. Hoffmann-La Roche Ag Compositions and methods of treating lupus nephritis
CN116981696A (zh) 2021-03-18 2023-10-31 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
EP4314063A1 (de) 2021-03-23 2024-02-07 Alector LLC Anti-tmem106b-antikörper zur behandlung und prävention von coronavirusinfektionen
GB202104104D0 (en) 2021-03-24 2021-05-05 Liliumx Ltd Platform and method
WO2022201122A1 (en) 2021-03-26 2022-09-29 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof
EP4314032A1 (de) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-aktivierte polypeptide
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
KR20230165911A (ko) 2021-04-09 2023-12-05 씨젠 인크. 항-tigit 항체를 사용한 암의 치료 방법
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
TW202305122A (zh) 2021-04-19 2023-02-01 美商建南德克公司 經修飾之哺乳動物細胞
EP4326271A1 (de) 2021-04-23 2024-02-28 F. Hoffmann-La Roche AG Vorbeugung oder abschwächung von nebenwirkungen im zusammenhang mit nk-zell-aktivierenden mitteln
JP2024509664A (ja) 2021-04-30 2024-03-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗cd20/抗cd3二重特異性抗体による治療のための投薬
CN117321078A (zh) 2021-04-30 2023-12-29 豪夫迈·罗氏有限公司 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
EP4334355A1 (de) 2021-05-03 2024-03-13 UCB Biopharma SRL Antikörper
EP4334343A2 (de) 2021-05-06 2024-03-13 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
CA3218170A1 (en) 2021-05-12 2022-11-17 Jamie Harue HIRATA Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20220389097A1 (en) 2021-05-14 2022-12-08 Genentech Inc. Agonists of TREM2
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
CN117396599A (zh) 2021-05-21 2024-01-12 基因泰克公司 用于生产目的重组产物的经修饰的细胞
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
AR126054A1 (es) 2021-06-04 2023-09-06 Chugai Pharmaceutical Co Ltd Anticuerpos anti-ddr2 y usos de estos
BR112023025738A2 (pt) 2021-06-09 2024-02-27 Hoffmann La Roche Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
WO2022266223A1 (en) 2021-06-16 2022-12-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
CN117545779A (zh) 2021-06-25 2024-02-09 中外制药株式会社 抗ctla-4抗体的用途
IL309115A (en) 2021-06-25 2024-02-01 Chugai Pharmaceutical Co Ltd Anti-CTLA-4 antibodies
CA3223534A1 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
WO2023288241A1 (en) 2021-07-14 2023-01-19 Genentech, Inc. Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
WO2023001884A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
IL309120A (en) 2021-07-28 2024-02-01 Hoffmann La Roche Methods and compositions for the treatment of cancer
WO2023012147A1 (en) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use
WO2023019239A1 (en) 2021-08-13 2023-02-16 Genentech, Inc. Dosing for anti-tryptase antibodies
AU2022332285A1 (en) 2021-08-23 2024-02-15 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
TW202328177A (zh) 2021-08-27 2023-07-16 美商建南德克公司 治療tau病理學之方法
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023062050A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
TW202325742A (zh) 2021-11-01 2023-07-01 瑞士商赫孚孟拉羅股份公司 使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2023088889A1 (en) 2021-11-16 2023-05-25 Apogenix Ag CD137 ligands
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023102367A1 (en) 2021-12-01 2023-06-08 Kadmon Corporation, Llc B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins
US20240018240A1 (en) 2021-12-10 2024-01-18 Hoffmann-La Roche Inc. Antibodies binding to cd3 and plap
WO2023110788A1 (en) 2021-12-14 2023-06-22 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/mage-a4 x cd3 bispecific antibody and a 4-1bb (cd137) agonist
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
TW202340248A (zh) 2021-12-20 2023-10-16 瑞士商赫孚孟拉羅股份公司 促效性ltbr抗體及包含其之雙特異性抗體
US20230227545A1 (en) 2022-01-07 2023-07-20 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗notch2抗體及結合物及其使用方法
WO2023147329A1 (en) 2022-01-26 2023-08-03 Genentech, Inc. Antibody-conjugated chemical inducers of degradation and methods thereof
WO2023147328A1 (en) 2022-01-26 2023-08-03 Genentech, Inc. Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2023170291A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
WO2023170295A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
TW202346355A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
TW202346365A (zh) 2022-03-23 2023-12-01 瑞士商赫孚孟拉羅股份公司 抗cd20/抗cd3雙特異性抗體及化學療法之組合治療
WO2023180503A1 (en) 2022-03-25 2023-09-28 Medimmune Limited Methods for reducing respiratory infections
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20230364020A1 (en) 2022-04-01 2023-11-16 Genentech, Inc. Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
US20230406930A1 (en) 2022-04-13 2023-12-21 Genentech, Inc. Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023209568A1 (en) 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20230416412A1 (en) 2022-05-31 2023-12-28 Hoffmann-La Roche Inc. Prevention or mitigation of t-cell engaging agent-related adverse effects
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024015993A1 (en) 2022-07-15 2024-01-18 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020579A1 (en) 2022-07-22 2024-01-25 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024040216A2 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. Anti-ccr8 antibodies and uses thereof
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132405A (en) * 1977-02-16 1979-01-02 Asher Nathan F Balanced swivel exercising device
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4479930A (en) * 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4938948A (en) * 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
JPS6360942A (ja) * 1986-08-01 1988-03-17 シタス コ−ポレイシヨン インタ−ロイキン−2と共に免疫毒素又は抗体を用いてのコンビネ−ション治療
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1988009344A1 (en) * 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2091824T3 (es) * 1989-04-21 1996-11-16 Us Health Proteina recombinante de fusion toxina anticuerpo.
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2100671C (en) * 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
JP3951062B2 (ja) * 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DK1136556T3 (da) * 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
RU2128709C1 (ru) * 1992-01-23 1999-04-10 Мерк Патент Гмбх Способ получения димерного одноцепочечного слитого белка (варианты)
EP1514934B1 (de) * 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Marker für Krebs und biosynthetisches Bindeprotein dafür
AU4025193A (en) * 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies

Also Published As

Publication number Publication date
JP2005168489A (ja) 2005-06-30
AU3612293A (en) 1993-09-03
CA2129663A1 (en) 1993-08-19
US5753204A (en) 1998-05-19
EP1997894A2 (de) 2008-12-03
EP1514934A3 (de) 2006-04-19
EP0625200B1 (de) 2005-05-11
AU675929B2 (en) 1997-02-27
JP2009035558A (ja) 2009-02-19
JP2007228979A (ja) 2007-09-13
JP4236493B2 (ja) 2009-03-11
CA2129663C (en) 2005-07-05
DE69334351D1 (de) 2011-05-12
JP2005104965A (ja) 2005-04-21
US5877305A (en) 1999-03-02
EP1514934A2 (de) 2005-03-16
EP1997894A3 (de) 2009-11-04
JP2008289500A (ja) 2008-12-04
ATE295420T1 (de) 2005-05-15
US5837846A (en) 1998-11-17
DE69333807T2 (de) 2006-02-02
US5534254A (en) 1996-07-09
EP1997894B1 (de) 2011-03-30
US20020168375A1 (en) 2002-11-14
EP0625200A1 (de) 1994-11-23
US7138497B2 (en) 2006-11-21
ATE503496T1 (de) 2011-04-15
US20060147444A1 (en) 2006-07-06
JP2007231027A (ja) 2007-09-13
ATE419355T1 (de) 2009-01-15
CA2372813A1 (en) 1993-08-19
JP2003284577A (ja) 2003-10-07
WO1993016185A3 (en) 1993-09-30
WO1993016185A2 (en) 1993-08-19
DE69333807D1 (de) 2005-06-16
EP1514934B1 (de) 2008-12-31
JPH08500962A (ja) 1996-02-06

Similar Documents

Publication Publication Date Title
ATE295420T1 (de) Marker für krebs und biosynthetisches bindeprotein dafür
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
CY1121451T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4
Kipriyanov et al. Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
WO2008028192A3 (en) Variable region sequences of il-31 monoclonal antibodies and methods of use
GB2286399A (en) Recombinant humanized anti-cytomegalovirus antibodies
DE60235079D1 (de) Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
ES2108732T3 (es) Anticuerpos humanizados anti-globulos de la grasa de la leche humana.
IL131406A0 (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
DE69119211T2 (de) Cdr-gepfropfte anti-cea-antikörper und ihre herstellung
WO1994004691A3 (en) Dimer and multimer forms of single chain polypeptides
HRP20150934T1 (hr) Djelovanje na abcb5 u terapiji raka
DE69029808D1 (de) Monoklonale antikörper
ATE508193T1 (de) Menschliches rezeptor für zytokine
Kipriyanov et al. Bacterial expression and refolding of single-chain Fv fragments with C-terminal cysteines
Muzard et al. Grafting of protein L-binding activity onto recombinant antibody fragments
GB2598698A (en) Affinity-maturated anti-ASICIa antibodies
Vola et al. Recombinant proteins L and LG: two new tools for purification of murine antibody fragments
KR20230062232A (ko) Native C3에 특이적으로 결합하는 항체 및 이를 포함하는 경도인지장애 진단용 조성물
RU2021139258A (ru) Dll3-нацеливающие антитела и их применения
Nilson The bacterial cell wall molecules protein G and protein L: Characterization and use of their immunoglobulin binding properties.
Young et al. The circular dichroism of phosphocholine-specific mouse hybridoma and myeloma proteins: unusual properties of the hybridoma protein 101.6 G6
CN117304327A (zh) 一种抗山羊IgG的兔单克隆抗体及其应用

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 1514934

Country of ref document: EP